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ABSTRACT  
Objective: The present work based on formulation of Ramipril tablets containing solid dispersion employing selective polymers. The objective 
of the preparation is to prepare the solid dispersion of the Ramipril, which has more responsive value in terms of the dissolution rate.  
Method: Solid dispersion complex was prepared with two different carriers PEG 6000 and PVP K30. Nine formulations were developed and  
each formulation were subjected to pre compression and post compression parameters. 
Result and Discussion:  Pre-compression and post compression parameters were studied which had shown good flow property and compiled 
the standard data. In-vitro dissolution studies shows more than 90 % drug release in phosphate buffer pH 6.8 in 30 min. Out of all formulation 
F4 showed 92.55±0.67 % drug release with in 30min which was the best result rest of the formulation.  
Conclusion: Ramipril tablets were successfully prepared and evaluated. F4 formulation shows the greater dissolution rate in phosphate buffer 
pH 6.8 as compared to other formulations. When compared with marketed formulation it also shows better results. Therefore, Ramipril solid 
dispersion tablets enhanced the dissolution rate and can be more efficacious for improving oral bioavailability of Ramipril.  
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INTRODUCTION 
One of the foremost difficult aspects pharmaceutical 
industries have long-faced is to boost the oral bioavailability 
of the poorly soluble medication. On an average 30-40% of 
newly discovered drug, candidates are poor water-soluble 
hence, it becomes necessary to enhance the solubility of the 
poorly water-soluble drugs.1, 2 
Ramipril is an inhibitor of angiotensin converting enzyme 
and it is a pro drug. Liver is responsible for converting 
Ramipril to the Ramiprilet and in a less extent converted in 
kidneys. ACE is accountable for converting ATI to ATII and 
Ramiprilat is a potent and effective inhibitor of ACE. 
Angiotensin II is the key constituent of RAAS and it regulates 
blood pressure.  For the treatment of hypertension, 
congestive heart failure and nephropathy, Ramipril is found 
to be useful.3, 4 
Ramipril hinders the RAAS system by binding to and 
inhibiting ACE thereby preventing the conversion of 
angiotensin I to angiotensin II. Angiotensin 1 receptor 
mediates vasoconstriction, inflammation, fibrosis, and 
oxidative stress through a variety of signaling pathways. As 
plasma levels of angiotensin II fall, less activation of the G-
protein coupled receptors angiotensin receptor I and 
angiotensin receptor II occurs. Angiotensin includes actions 
such as Gq coupling to the inositol tri-phosphate pathway, 
activation of phospholipases C, A2, and D which contribute to 
eicosanoid production, activation of Ca2+-dependent and 
MAP kinases, Gi and G12/13, and eventual activation of the 
Jak/STAT pathway leading to cell growth and production of 
extracellular matrix components. 
AT2R acts in opposition to the effects of AT1R by activating 
phosphotyrosine phosphatases, which inhibit MAP kinases, 
inhibiting Ca2+ channel opening, and stimulating cGMP and 
nitric oxide production leading to vasodilation.5, 6 
According to the Bio pharmaceutics Classification System 
(BCS), Ramipril is a Class II having low solubility and high 
permeability. In the Present Study, formulation of Ramipril 
tablets containing solid dispersion employing selective 
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polymers were prepared to enhanced the dissolution rate 
that will leads to the increased bioavailability.  
MATERIALS AND METHODS 
Ramipril was obtained as a gift sample from SGPTC Pvt Ltd. 
Polymers like, PEG 6000, Cross caramellose sodium (CCS), 
Crospovidone (CP), Sodium starch glycolate (SSG) were 
procured from CDH Fine Chemicals New Delhi and all other 
chemicals were procured from SD Fine-chem. Ltd, Mumbai. 
The entire chemicals were used of Analytical Grade. 
Pre-formulation studies 
All the Preformulation studies like melting point, solubility 
study, and partition coefficient were carried out effectively.7-
9 
Estimation of Ramipril 
Determination of max of Ramipril 
A 10 µg/ml solution of Ramipril in methanol was scanned in 
the range of 200-400 nm. 10 
Preparation of standard curve of Ramipril in methanol 
The standard stock solution of Ramipril (1mg/ml) was 
prepared in methanol. This solution was diluted with 
methanol, to obtain various dilutions from 2-20 µg/ml. 
Absorbance of these solutions was recorded at 210nm 
against methanol as blank using UV-visible 
spectrophotometer and standard curve was plotted against 
concentration. From the calibration curve intercept, slope, 
straight-line equation and correlation coefficient were 
obtained. 
FTIR of Ramipril and Excipients 
The samples were triturated and mixed well with potassium 
bromide in the ratio 1:100. Then the mixture was introduced 
in the sample holder and scanned to obtain the graphs in the 
range of 4000–400 cm-1. The spectra of pure drug and drug 
with excipients were compared to check any incompatibility 
and physical changes. 11 
Preparation of Solid Dispersion 
Freeze drying method was used for the preparation of solid 
dispersion. Accurately weighed drug, PEG6000, and PVP K30 
in mM ratio of 1:1mM was dissolved in 1:1mM solution of 
methanol: water to get a clear solution. Both the solutions 
were mixed and were stirred for 24 hour at a controlled 
temperature (40 ± 1˚C) to remove the organic solvent. The 
obtained solution was filtered, gradually cooled down to 
room temperature, and then placed in a refrigerator at 
−20˚C. The fully frozen solution was dried in a vacuum freeze 
dryer, and the resulting solid complexes were collected. 12 
Evaluation of Solid Dispersion 
Micromeretic properties 
Micromeretics Properties like Bulk Density, tapped density, 
angle of repose, Carr’s index and hausner ratio were 
evaluated. 13 
Solubility Study of Solid Dispersion Complex 
Excess quantities of pure drug (20 mg) and its inclusion 
complexes were added to 5 ml of distilled water to obtain 
supersaturated solutions. The solutions were continuously 
stirred for 24h at 25˚C. After 24h each sample was 
centrifuged at 15000 rpm and supernatant was withdrawal. 
After that supernatant was filtered and filtrate was suitably 
diluted and determined spectrophotometrically at 210 nm.  
Determination of Drug content  
Drug: PEG6000 complex equivalent to 10 mg of drug was 
stirred for 60 minutes with 100 ml of methanol, then filtered 
and handled as 100μg / ml inventory solution. The level of 
10μg / ml was prepared from this inventory solution and the 
medication content was determined using the methanol 
spectrophotometric calibration curve of pure medication at 
210 nm using methanol as void. 14 
In-vitro dissolution studies of Solid Dispersion 
Studies of drug release using USP apparatus II at 75 rpm 
were conducted in triplicate at 37 ± 0.5 ° C. Two dissolution 
media (Phosphate buffer pH 6.8 and 0.1N (HCl)) were used 
for the dissolution research. Dissolution studies were 
performed on pure drug (10 mg) and the complex containing 
an equivalent amount of the drug. At pre-specified time 
intervals, 0.25min, 0.5min, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 
hrs., samples (5 ml) were extracted and replaced with an 
equal volume of the same dissolution medium maintained at 
37˚C and were analyzed spectrophotometrically at 210 nm. 14 
Formulation of Ramipril Solid Dispersion Tablets 
The tablets were prepared in accordance with the formula 
provided in Table 5 by direct compression technique. All 
ingredients except magnesium stearate were carried through 
mesh #18. Stearate of magnesium was carried through mesh 
#22. Solid dispersion equal to 10 mg of drug and 
superdisintegrants were mixed by taking tiny portions of 
each in ascending order and blended into a mortar to obtain 
a uniform combination. The other ingredients were weighed 
and mixed in geometric order and tablets were compressed 
using a single punching machine with 8 mm round flat 
punches. 15 
 
Table 1: Composition of Ramipril Tablets 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Drug solid dispersion (equivalent to 10mg) 26 26 26 26 26 26 26 26 26 
Cross caramellose sodium (CCS) 8 16 20 - - - - - - 
Menthol 15 15 15 15 15 15 15 15 15 
Sodium starch glycolate (SSG) - - - - - - 8 16 20 
Micro crystalline cellulose 132 124 120 132 124 120 132 124 120 
Magnesium stearate 4 4 4 4 4 4 4 4 4 
Talc 3 3 3 3 3 3 3 3 3 
Crospovidone (CP) - - - 8 16 20 - - - 
D-sorbitol 12 12 12 12 12 12 12 12 12 
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Evaluation of Tablets 
Pre-compression studies like bulk density, tapped density, 
angle of repose, Carr’s index and Hausner’s ration were 
carried out successfully 
Post Compression Studies 
The prepared tablets were evaluated for post compression 
studies, which are as follows: 
Weight variation 
 20 tablets were selected randomly from a batch and were 
individually weighed and then the average weight was 
calculated. The individual weight was then compared with 
the average value to find the deviation in weight.16 
Hardness 
The device measures the force needed to break the tablet 
when it reaches the tablet with the force produced by 
plungers. The tablet was positioned between two plungers; 
force was applied to the plungers and the crushing power 
was registered which only causes the tablet to break. From 
each formulation, the crushing force test was conducted on 5 
tablets. 16 
Friability 
Pre-weighed tablets (20) were placed in Roche friabilator 
and were subjected to 100 revolutions at 25rpm for 4 
minutes at a height of 6 inches. The tablets were de-dusted 
and reweighed. It is calculated by the formula:  
Friability % = 
                         
             
      
Thickness 
The tablet thickness was determined using a caliper from 
Vernier. Five tablets were used and average values were 
calculated from each formulation type. 17 
In-vitro disintegration time  
Place one tablet in each of the basket's six pipes. Add a disk 
to each tube and run the device using distilled water as the 
immersion liquid maintained at 37 ° ± 2 ° C. In the 0.1 N HCl 
maintained at 37 ° ± 2 ° C, the assembly should be raised and 
lowered between 30 cycles per minute. The time taken in 
seconds to disintegrate the tablet completely without any 
palpable mass left in the device was measured and 
registered. 17 
In-vitro dissolution studies 
Using USP type-II devices (50 rpm), using 900ml of 0.1 N HCl 
and Phosphate Buffer pH 6.8 as a dissolution medium, 
dissolution rate was researched. The dissolution medium 
temperature has been maintained at 37 ± 0.5 ° C. At a 
predetermined time interval (5, 10, 15, 20, 25, 30 min) 5ml 
of the sample was removed and replaced by the fresh 
medium at every 5 min interval. The absorption of the 
filtered solution was assessed at 210 nm using a UV 
spectrophotometric technique and the drug concentration 
was determined from the normal calibration curve. 18 
RESULT AND DISCUSSION 
Pre-Formulation 
The selected drug Ramipril was subjected for investigation 
of physical characterization parameters such as: 
organoleptic properties, melting point, solubility, partition 
coefficient and were find with in the acceptance criteria as 
per IP.  
Determination of absorption of Ramipril in methanol 
The absorption maxima of Ramipril were obtained in 
methanol and it was found 210 nm. Calibration curve 
obtained from different concentration shows good 
regression value of 0.9925. 
 
 
Figure 1: UV Spectrum of Ramipril in methanol 
 
Table 2: Calibration curve of Ramipril in methanol 
Concentration (µg/ml) Absorbance (mean±SD) 
2 0.149±0.001 
4 0.256±0.001 
6 0.373±0.001 
8 0.486±0.002 
10 0.58±0.007 
12 0.671±0.008 
14 0.743±0.006 
16 0.824±0.007 
18 0.901±0.008 
 
 
 
Figure 2: Standard calibration curve of Ramipril in 
methanol
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FTIR of Ramipril and Excipients 
In case of PEG 6000, the spectrum was characterized by the 
appearance of broad band at 3383 cm-1 which corresponds 
to the OH group. The band at 1232 cm-1 is for C–O stretching. 
For the binary SD with PEG 6000, the spectrum is the sum of 
the spectra of the drug and polymer with the main bands 
being clear. This suggests absence of any interaction 
between the drug and PEG 6000 (Figure 3). 
 
Figure 3: FTIR Spectrum of (a) pure drug (b) PEG6000 (c) Solid dispersion 
 
Evaluation of solid dispersion 
Micromeretic properties 
After studying the flow properties it was found that angle of 
repose has value of 27.87, which means powder will possess 
good flow property. The bulk density was found to be 0399 
g/cm3. Tapped density was observed as 0.477 g/cm3. Carr’s 
index was found to be 15.840 % indicates a good flow ability 
of the powder blend. Hausner’s ratio was found to be 1.194. 
All the flow property parameters were studied thoroughly 
and all the properties compile the standard data, so we can 
say that solid dispersion show good flow property and data 
are shown in Table 3. 
 
 
Table 3: Micrometrics properties of solid dispersion 
Angle of Repose (o) Bulk density (g/cm3) 
Tapped density 
(g/cm3) 
Carr’s Index 
(%) 
Hausner’s 
ratio 
27.87 ± 1.18 0.39 ± 0.01 0.47 ± 0.04 15.84 ± 0.80 1.19 ± 0.10 
Mean ± SD; n = 3 
 
 
 
Kumar et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):142-149 
ISSN: 2250-1177                                                                                  [146]                                                                                 CODEN (USA): JDDTAO 
Solubility study of the complex solid dispersion  
After complexation with PEG6000 and PVP K30, Ramipril 
exhibits remarkable enhancement solubility, increasing from 
0.025 mg/mL to 7.54 mg/mL and 1.50 mg/mL respectively. 
While both complexes show significant Ramipril 
solubilization, comparison of the solubility’s of the two 
complexes indicates that the solubility of the PEG6000 
complex is several times higher than that of the PVP K30 
complex. These solubilization results demonstrate that 
PEG6000 is a more efficient solubilizer than PVP K30, thus, 
PEG6000 was selected for further formulation and 
evaluation studies. 
 
Table 4: Solubility of Pure drug and solid dispersion Phosphate Buffer pH 6.8 
Samples Solubility (mg/ml) 
Pure drug 0.025±0.006 
PEG 6000-solid dispersion 7.54±0.021 
PVP K30- solid dispersion 1.50±0.004 
 
 
Determination of Drug content 
The drug content of the complex formed was found to be 
86.09 ± 0.535 %. 
In-vitro dissolution studies 
Dissolution study shows that the dissolution rate of Ramipril 
has been enhanced largely. The drug release with PEG6000 
was 77.42 ± 0.398 % in 0.1N HCl and of pure drug was 52.59 
± 0.481 % and the drug release with PEG6000 was 79.40 ± 
0.292 % in phosphate buffer pH 6.8 (PBS 6.8) and of pure 
drug was 58.78 ± 0.382 %. Enhanced solubility and 
improved dissolution were obtained by solid dispersion in 
both PBS 6.8 and hydrochloric acid. Data are tabulated in 
Table 5. 
 
Table 5: Percentage drug release of pure drug and Drug-PEG6000 solid dispersion complex in 0.1N HCl and phosphate 
buffer pH 6.8 
Time (hrs) 0.1N HCl Phosphate buffer pH 6.8 
 Pure Drug (%) Complex (%) Pure Drug (%) Complex (%) 
0 0 0 0 0 
0.25 1.40±0.39 8.48±0.72 4.02±0.33 15.31±0.95 
0.5 5.55±0.38 13.78±0.38 8.17±0.48 19.65±0.48 
1 8.48±0.48 17.68±0.58 12.44±0.95 22.72±0.58 
2 12.06±0.69 22.91±0.29 15.51±0.57 26.42±0.57 
3 15.76±0.48 25.65±0.50 20.48±0.87 31.53±0.77 
4 19.72±0.38 31.21±0.19 25.14±0.77 36.44±0.67 
5 24.06±0.22 35.68±0.48 29.36±0.86 42.06±0.96 
6 28.27±0.29 38.61±0.61 33.63±0.58 46.59±0.79 
7 31.27±0.67 44.48±0.58 39.82±0.69 51.14±0.39 
8 36.31±0.67 49.78±0.57 45.76±0.76 56.87±0.76 
9 41.23±0.48 56.42±0.48 49.85±0.29 60.06±0.72 
10 46.85±0.48 62.48±0.58 53.55±0.96 63.0±0.83 
12 50.29±0.48 69.12±0.69 56.17±0.67 72.95±0.66 
24 52.46±0.50 77.42±0.39 58.78±0.38 79.40±0.29 
Mean ± SD; n = 3 
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(a)                                                                                                 (b) 
Figure 4: % drug release of drug and its complex in 0.1N HCl (left) and Phosphate buffer pH 6.8 (right) 
 
Evaluation of tablets 
Pre compression parameters 
All the pre-compression parameters were studied 
thoroughly and all the properties compile the standard data, 
so we can say that solid dispersion show good flow property 
and data are shown in Table 6. 
 
Table 6: Pre compression parameters of Ramipril solid dispersion powder blend 
Formulation 
code 
Angle of repose (˚C) Bulk density (g/cm3) 
Tapped density 
(g/cm3) 
Carr’s index (%) Hausner’s ratio 
F1 29.40 ± 2.81 0.354 ±0.003 0.384±0.009 7.78±1.61 1.08±0.018 
F2 23.21 ± 0.66 0.312±0.005 0.348±0.008 10.38±0.915 1.11±0.011 
F3 20.93± 0.96 0.375± 0.014 0.446± 0.024 15.79±1.50 1.18±0.020 
F4 20.15± 1.68 0.306± 0.012 0.337± 0.016 9.14± 0.959 1.10± 0.011 
F5 23.17± 2.61 0.327± 0.001 0.398± 0.006 18.00± 1.82 1.21± 0.027 
F6 27.46 ± 2.15 0.336± 0.005 0.385± 0.007 12.81± 1.21 1.14± 0.016 
F7 25.96 ± 1.37 0.316 ± 0.008 0.361± 0.005 12.43± 1.15 1.14± 0.014 
F8 27.08 ±2.50 0.321±0.002 0.353±0.005 9.17±1.54 1.10±0.018 
F9 29.28±1.78 0.301±0.002 0.341±0.004 11.61±1.40 1.13±0.017 
Mean ± SD; n = 3 
 
Post Compression Parameters 
All formulation were subjected to post evaluation 
parameters viz. hardness, thickness, friability, weight 
variation, disintegration time, drug content and in-vitro 
dissolution studies. Each formulation passes all the 
parameters (Table 7). In-vitro dissolution studies was done 
in 1N HCl and phosphate buffer pH 6.8 buffer solution. In 
dissolution studies formulation F4 shows best result in both 
the dissolution medium. In 0.1N HCl it shows 86.55±0.69 % 
and in phosphate buffer pH 6.8 dissolution release was 
92.55±0.67 % in 30min (Table 8, 9). Therefore, we can say 
that phosphate buffer pH 6.8 shows better result as 
compared of 0.1N HCl. The best formulation F4 were than 
compared with marketed formulation and data is shown in 
Table 10. 
 
Table 7: Post-compression parameters of Ramipril Tablets 
Formulation 
code 
Hardness 
(kg/cm2) 
Thickness (mm) Friability (%) 
Disintegration 
time (sec) 
Drug Content  
F1 4.10±0.560 3.38±0.025 0.634 ± 0.073 59.57 ± 0.577 98.3±0.436 
F2 4.01± 0.025 3.44±0.020 0.468 ± 0.094 58.35 ± 0.673 98.2±0.410 
F3 4.04± 0.011 3.37± 0.025 0.580 ± 0.066 61.70 ± 0.608 99.6±0.071 
F4 4.08±0.075 3.44± 0.040 0.345 ± 0.064 51.20 ± 0.779 99.2± 0.089 
F5 4.42±0.015 3.29± 0.020 0.569 ± 0.101 70.10 ± 0.850 98.3±0.121 
F6 4.41± 0.015 3.45± 0.020 0.452 ± 0.106 73.30 ± 0.557 97.4±0.520 
F7 4.82± 0.015 2.99± 0.047 0.323 ± 0.072 59.90 ± 0.500 97.8± 0.520 
F8 4.75±0.017 2.93±0.040 0.659 ± 0.129 72.06 ± 0.416 97.2±0.263 
F9 4.03±0.015 2.87±0.020 0.655 ± 0.046 68.36 ± 0.416 96.3±0.473 
Mean ± SD; n = 3 
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Table 8: Percentage drug release of Ramipril Tablets in 0.1N HCl 
Time 
(min) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
5 39.76±0.58 44.61±0.38 41.36±0.69 46.46±0.29 38.46±0.48 45.66±0.39 39.46±0.59 38.36±0.49 42.31±0.48 
10 43.53±0.39 47.93±0.79 46.65±0.61 51.76±0.48 41.33±0.29 55.96±0.48 44.85±0.21 42.25±0.61 48.23±0.79 
15 47.42±0.29 51.51±0.33 52.59±0.67 62.44±0.76 54.42±0.19 56.94±0.76 53.69±0.67 48.59±0.77 51.71±0.33 
20 59.57±0.67 55.27±0.67 57.38±0.58 70.78±0.58 62.47±0.44 68.48±0.18 60.48±0.48 57.18±0.18 54.37±0.67 
25 64.76±0.50 60±0.94 60.38±0.79 82.59±0.58 72.76±0.70 78.59±0.98 64.48±0.69 63.78±0.59 62.1±0.54 
30 79.55±0.57 68±0.38 69.53±0.76 86.55±0.69 78.85±0.57 83.35±0.29 70.23±0.76 68.23±0.46 73.3±0.37 
 Mean ± SD; n = 3 
Table 9: Percentage Drug Release of Ramipril Tablets in Phosphate Buffer pH 6.8 
Time 
(min) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
5 41.48±0.48 48.51±0.86 53.29±0.58 49.65±0.58 48.31±0.46 44.48±0.48 46.25±0.25 42.24±0.68 43.29±0.54 
10 51.63±0.57 50.29±0.48 57.19±0.79 54.57±0.76 54.19±0.88 48.63±0.57 54.41±0.28 54.19±0.59 54.79±0.39 
15 64.51±0.86 59.06±0.22 61.72±0.39 61.59±0.79 64.06±0.22 54.51±0.86 59.46±0.52 58.42±0.39 61.12±0.28 
20 68.46±0.61 66.36±0.57 66.44±0.57 76.72±0.77 72.56±0.67 68.46±0.61 64.41±0.23 62.44±0.47 69.34±0.27 
25 70.51±0.58 74.59±0.39 69.31±0.95 84.31±0.79 79.49±0.29 73.51±0.58 72.19±045 68.41±0.45 78.41±0.25 
30 83.46±0.39 85.12±0.87 72.44±0.77 92.55±0.67 85.42±0.17 77.46±0.39 81.12±0.74 79.14±0.14 84.34±0.51 
Mean ± SD; n = 3 
 
Figure 5: Percent drug release of all formulation (a) 0.1N HCl (b) Phosphate buffer pH 6.8 
 
  Table 10: Percentage drug release of optimized 
formulation (F4) with marketed formulation in 
phosphate buffer pH 6.8 
Time (min) 
Formulation 
F4 
Marketed 
Formulation 
0 0 0 
5 49.65±0.58 48.74±0.72 
10 54.57±0.76 55.53±0.48 
15 66.59±0.79 63.46±0.77 
20 79.72±0.77 77.36±0.29 
25 90.31±0.79 84.82±0.57 
30 92.45±0.67 88.45±0.98 
 
 
Figure 6: Percent drug release of optimized formulation 
(F4) with marketed formulation in phosphate buffer pH 
6.8 
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CONCLUSION 
The present work was based on the enhancement of the 
dissolution rate of Ramipril tablet by solid dispersion 
technique. Solid dispersion complex was prepared with two 
different carriers PEG 6000 and PVP K30. Phase solubility 
study of the PEG6000- complex had shown greater stability 
constant. FTIR studies of PEG 6000 with complex showed no 
interaction. The micromeretic properties of the solid 
dispersion was studied and showed good flow properties. 
Nine formulations were developed and pre-compression 
parameters were studied which had shown good flow 
property and compiled the standard data. In the post 
compression parameters, all formulation shows good results. 
Formulation F4 showed 92.55±0.67 % drug release in 
phosphate buffer pH 6.8 and 86.55±0.69 % in 0.1N HCl as 
compared to other formulation. The best formulation were 
compared with marketed formulation and shows greater 
result i.e. 92.45±0.67 % drug release in 30min. Therefore, 
Ramipril solid dispersion tablets have shown maximum drug 
release, and can be more efficacious for improving oral 
bioavailability of Ramipril. 
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